^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Circ0003039

    i
    Other names: Circ0003039
    Associations

    News

    Trials
    Company:
    Sun Yat-sen University
    Drug class:
    Wnt signalling pathway inhibitor, CALR protein degrader
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Circ0003039 interacts with calreticulin to inhibit the progression of hepatocellular carcinoma by suppressing wnt/beta-catenin signaling pathway (AACR 2023)
    Our study demonstrates that circ0003039 bind to N-terminal domain of CALR and facilitated CAPN2 to degrade CALR protein, which inhibits the development and progression of HCC via suppressing CALR-mediated wnt-βcatenin signaling pathway, and circ0003039 is a potential prognostic biomarker and therapeutic target for HCC.
    Late-breaking abstract
    |
    CALR (Calreticulin) • CAPN2 (Calpain 2)
    |
    Circ0003039